Philip PA - Search Results

1

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.

Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. Khan HY, et al. Among authors: philip pa. Cancer Res Commun. 2022 May;2(5):342-352. doi: 10.1158/2767-9764.crc-21-0176. Epub 2022 May 10. Cancer Res Commun. 2022. PMID: 35573474 Free PMC article.

2

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.

Zalupski MM, Philip PA, LoRusso P, Shields AF. Zalupski MM, et al. Among authors: philip pa. Cancer Chemother Pharmacol. 1997;40(3):225-7. doi: 10.1007/s002800050650. Cancer Chemother Pharmacol. 1997. PMID: 9219505 Clinical Trial.

3

A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer.

Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. Philip PA, et al. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88. Semin Oncol. 1997. PMID: 9427274 Clinical Trial.

4

Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.

Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V. Zalupski MM, et al. Among authors: philip pa. Invest New Drugs. 1998;16(1):93-6. doi: 10.1023/a:1006087114621. Invest New Drugs. 1998. PMID: 9740550 Clinical Trial.

5

Phase II study of CI-958 in colorectal cancer.

Shields AF, Philip PA, LoRusso PM, Ferris AM, Zalupski MM. Shields AF, et al. Among authors: philip pa. Cancer Chemother Pharmacol. 1999;43(2):162-4. doi: 10.1007/s002800050878. Cancer Chemother Pharmacol. 1999. PMID: 9923823 Clinical Trial.

6

Gemcitabine and UFT plus oral calcium folinate: phase I study.

Philip PA, Ibrahim D, Zalupski M, Arlauskas P, Shields A. Philip PA, et al. Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):116-9. Oncology (Williston Park). 1999. PMID: 10442378 Free article. Clinical Trial.

7

A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.

Zonder JA, Shields AF, Zalupski M, Chaplen R, Heilbrun LK, Arlauskas P, Philip PA. Zonder JA, et al. Among authors: philip pa. Clin Cancer Res. 2001 Jan;7(1):38-42. Clin Cancer Res. 2001. PMID: 11205915 Clinical Trial.

8

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF. Philip PA, et al. Cancer. 2001 Aug 1;92(3):569-77. doi: 10.1002/1097-0142(20010801)92:3<569::aid-cncr1356>3.0.co;2-d. Cancer. 2001. PMID: 11505401 Clinical Trial.

9

Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.

Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Merati K, et al. Am J Clin Oncol. 2001 Oct;24(5):447-52. doi: 10.1097/00000421-200110000-00007. Am J Clin Oncol. 2001. PMID: 11586094

10

Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.

Mohammad RM, Adsay NV, Philip PA, Pettit GR, Vaitkevicius VK, Sarkar FH. Mohammad RM, et al. Among authors: philip pa. Anticancer Drugs. 2001 Oct;12(9):735-40. doi: 10.1097/00001813-200110000-00005. Anticancer Drugs. 2001. PMID: 11593055

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page